ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $12.50.

ALXO has been the subject of a number of analyst reports. Lifesci Capital lowered shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a research note on Tuesday, August 13th. Stifel Nicolaus reiterated a “hold” rating and set a $3.00 price objective (down from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th. UBS Group reduced their target price on ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a report on Friday, August 16th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Monday, August 12th.

ALX Oncology Price Performance

NASDAQ ALXO opened at $1.45 on Friday. ALX Oncology has a 1 year low of $1.34 and a 1 year high of $17.83. The business’s fifty day moving average is $1.85 and its two-hundred day moving average is $6.51. The stock has a market capitalization of $76.37 million, a P/E ratio of -0.40 and a beta of 1.03. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.39 and a current ratio of 4.39.

ALX Oncology (NASDAQ:ALXO) last announced its earnings results on Thursday, August 8th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.01. On average, research analysts forecast that ALX Oncology will post -3.04 earnings per share for the current fiscal year.

Institutional Trading of ALX Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the company. CANADA LIFE ASSURANCE Co acquired a new stake in ALX Oncology in the first quarter valued at approximately $27,000. EntryPoint Capital LLC bought a new position in shares of ALX Oncology during the 1st quarter valued at $32,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after purchasing an additional 5,200 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after purchasing an additional 6,888 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new stake in ALX Oncology in the second quarter worth $63,000. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.